Tom Powles/X
Jan 27, 2025, 15:58
Tom Powles: Bladder sparing approaches after EVP is likely to be the SoC in MIBC
Tom Powles, Professor at the University of London, shared a post on X:
“The muscle invasive bladder cancer session AUC3 discussed perioperative durvalumab + ctDNA are changing the disease. Also, pCR of >50% is expected with EVP. Bladder sparing approaches after EVP is likely to be the standard of care if this is the case.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 16, 2025, 18:35
Jun 16, 2025, 16:15
Jun 16, 2025, 16:01
Jun 16, 2025, 15:19